Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ARAY declined for three days, in 250 of 293 cases, the price declined further within the following month. The odds of a continued downward trend are 85%.
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARAY as a result. In 84 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for ARAY turned negative on October 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 41 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
ARAY moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARAY crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.
ARAY broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ARAY entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +12.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARAY advanced for three days, in 156 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.859) is normal, around the industry mean (10.930). P/E Ratio (86.490) is within average values for comparable stocks, (100.178). Projected Growth (PEG Ratio) (2.060) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.070) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. ARAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
BNGO saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 30, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 40 instances where the indicator turned negative. In 36 of the 40 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BNGO as a result. In 75 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
BNGO moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
BNGO broke above its upper Bollinger Band on September 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The RSI Indicator entered the oversold zone -- be on the watch for BNGO's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for BNGO moved above the 200-day moving average on September 28, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +1.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNGO advanced for three days, in 166 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 36 of 61 cases where BNGO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.626) is normal, around the industry mean (5.011). P/E Ratio (0.002) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (56.074).
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. BNGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
ARAY | BNGO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 23 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 93 | 62 | |
P/E GROWTH RATING 1..100 | 33 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BNGO's Valuation (23) in the Biotechnology industry is somewhat better than the same rating for ARAY (88) in the Medical Specialties industry. This means that BNGO’s stock grew somewhat faster than ARAY’s over the last 12 months.
BNGO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARAY (100) in the Medical Specialties industry. This means that BNGO’s stock grew similarly to ARAY’s over the last 12 months.
BNGO's SMR Rating (98) in the Biotechnology industry is in the same range as ARAY (98) in the Medical Specialties industry. This means that BNGO’s stock grew similarly to ARAY’s over the last 12 months.
BNGO's Price Growth Rating (62) in the Biotechnology industry is in the same range as ARAY (93) in the Medical Specialties industry. This means that BNGO’s stock grew similarly to ARAY’s over the last 12 months.
ARAY's P/E Growth Rating (33) in the Medical Specialties industry is significantly better than the same rating for BNGO (100) in the Biotechnology industry. This means that ARAY’s stock grew significantly faster than BNGO’s over the last 12 months.
| ARAY | BNGO | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 70% | 3 days ago 75% |
| Stochastic ODDS (%) | 3 days ago 77% | 3 days ago 89% |
| Momentum ODDS (%) | 3 days ago 85% | 3 days ago 87% |
| MACD ODDS (%) | 3 days ago 84% | 3 days ago 90% |
| TrendWeek ODDS (%) | 3 days ago 86% | 3 days ago 89% |
| TrendMonth ODDS (%) | 3 days ago 86% | 3 days ago 90% |
| Advances ODDS (%) | 14 days ago 73% | 5 days ago 77% |
| Declines ODDS (%) | 3 days ago 85% | 7 days ago 89% |
| BollingerBands ODDS (%) | 3 days ago 83% | 5 days ago 90% |
| Aroon ODDS (%) | 3 days ago 85% | 3 days ago 59% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARAY’s FA Score shows that 1 FA rating(s) are green while BNGO’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARAY’s TA Score shows that 3 TA indicator(s) are bullish while BNGO’s TA Score has 5 bullish TA indicator(s).
ARAY (@Medical/Nursing Services) experienced а -32.22% price change this week, while BNGO (@Pharmaceuticals: Other) price change was -12.89% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -6.10%. For the same industry, the average monthly price growth was -8.07%, and the average quarterly price growth was -16.10%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.71%. For the same industry, the average monthly price growth was -3.86%, and the average quarterly price growth was +3.30%.
ARAY is expected to report earnings on Nov 11, 2026.
BNGO is expected to report earnings on Oct 29, 2026.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (-1.71% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
A.I.dvisor indicates that over the last year, ARAY has been loosely correlated with ILMN. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ARAY jumps, then ILMN could also see price increases.
| Ticker / NAME | Correlation To ARAY | 1D Price Change % | ||
|---|---|---|---|---|
| ARAY | 100% | -10.41% | ||
| ILMN - ARAY | 41% Loosely correlated | -2.01% | ||
| A - ARAY | 41% Loosely correlated | -1.47% | ||
| ICUI - ARAY | 40% Loosely correlated | -2.54% | ||
| NVST - ARAY | 39% Loosely correlated | -2.55% | ||
| WRBY - ARAY | 38% Loosely correlated | -5.08% | ||
More | ||||